K. Dewulf MD, A-S. Van Rompuy MD, PhD, G. De Meerleer MD, PhD, K. Goffin MD, PhD, C. Mai MD, H. erlinde Dumez MD, PhD, M. Albersen MD, PhD
Metastatic penile cancer patients have a poor prognosis of six to twelve months with conventional therapies including surgery, cytotoxic chemotherapy and radiotherapy. We present the promising result of the use of an immune checkpoint inhibitor in a metastatic penile cancer patient. A review of the potential for immuno-therapy in penile cancer is presented.